|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 156.33 USD | +1.37% |
|
+0.19% | +13.48% |
| 05:00pm | UK Regulator OKs Novartis' Treatment for Chronic Spontaneous Urticaria | MT |
| 08-05 | Sandoz gains on strong biosimilar growth, touts 'golden decade' | RE |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Neutral | Neutral | Bullish |
| Resistance | 159.9 | 168.62 | 168.62 |
| Spread/Res. | -2.16% | -7.22% | -7.22% |
| Spread/Supp. | +4.61% | +9.45% | +8.67% |
| Support | 149.56 | 142.94 | 143.97 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- NOVN Stock
- NVS Stock
- Charts Novartis AG
Select your edition
All financial news and data tailored to specific country editions
